Protalix BioTherapeutics, Inc. Annual Deferred Income Tax Expense (Benefit) in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Protalix BioTherapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2021 to 2023.
  • Protalix BioTherapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$69K, a 97.8% increase year-over-year.
  • Protalix BioTherapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$3.09M.
  • Protalix BioTherapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $0.000.
Deferred Income Tax Expense (Benefit), Annual (USD)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$3.09M -$3.09M Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 $0 $0 Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $0 Jan 1, 2021 Dec 31, 2021 10-K 2024-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.